Gallardo-Rincón Dolores, Montes-Servín Edgar, Alamilla-García Gabriela, Montes-Servín Elizabeth, Bahena-González Antonio, Cetina-Pérez Lucely, Morales Vásquez Flavia, Cano-Blanco Claudia, Coronel-Martínez Jaime, González-Ibarra Ernesto, Espinosa-Romero Raquel, María Alvarez-Gómez Rosa, Pedroza-Torres Abraham, Castro-Eguiluz Denisse
Ovarian and Endometrial Cancer Program (COE), Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Department of Medical Oncology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Front Genet. 2022 Jun 6;13:863956. doi: 10.3389/fgene.2022.863956. eCollection 2022.
Ovarian cancer (OC) is gynecologic cancer with the highest mortality rate. It is estimated that 13-17% of ovarian cancers are due to heritable mutations in and . The (-Del ex9-12) Mexican founder mutation is responsible for 28-35% of the cases with ovarian cancer. The aim was to describe the PFS of OC patients treated with olaparib, emphasizing patients carrying the Mexican founder mutation (-Del ex9-12). In this observational study, of 107 patients with m, 35 patients were treated with olaparib from November 2016 to May 2021 at the Ovarian Cancer Program (COE) of Mexico; patient information was extracted from electronic medical records. Of 311 patients, 107 (34.4%) were with m; 71.9% (77/107) were with , of which 27.3% (21/77) were with -Del ex9-12, and 28.1% (30/107) were with mutations. Only 35 patients received olaparib treatment, and the median follow-up was 12.87 months. The PFS of -Del ex9-12 was NR (non-reach); however, 73% of the patients received the treatment at 36 vs. 11.59 months (95% CI; 10.43-12.75) in patients with other m ( = 0.008). Almost 50% of patients required dose reduction due to toxicity; the most frequent adverse events were hematological in 76.5% and gastrointestinal in 4%. Mexican OC -Del ex9-12 patients treated with olaparib had a significant increase in PFS regardless of the line of treatment compared to other mutations in .
卵巢癌（OC）是死亡率最高的妇科癌症。据估计，13% - 17%的卵巢癌是由BRCA1和BRCA2的遗传性突变引起的。BRCA2（-Del ex9 - 12）墨西哥始祖突变导致28% - 35%的卵巢癌病例。目的是描述接受奥拉帕利治疗的OC患者的无进展生存期（PFS），重点关注携带墨西哥始祖突变（-Del ex9 - 12）的患者。在这项观察性研究中，107例晚期卵巢癌患者中，有35例患者于2016年11月至2021年5月在墨西哥卵巢癌项目（卓越中心）接受了奥拉帕利治疗；患者信息从电子病历中提取。在311例患者中，107例（34.4%）为晚期卵巢癌；71.9%（77/107）携带BRCA2突变，其中27.3%（21/77）携带 -Del ex9 - 12突变，28.1%（30/107）携带其他BRCA2突变。只有35例患者接受了奥拉帕利治疗，中位随访时间为12.87个月。携带 -Del ex9 - 12突变患者的PFS未达到（NR）；然而，73%的携带该突变患者在36个月时仍接受治疗，而其他BRCA2突变患者为11.59个月（95%置信区间；10.43 - 12.75）（P = 0.008）。近50%的患者因毒性需要减量；最常见的不良事件是血液学方面的，占76.5%，胃肠道方面的占4%。与其他BRCA2突变相比，接受奥拉帕利治疗的携带墨西哥OC -Del ex9 - 12突变的患者无论治疗线数如何，PFS均显著增加。
